Published 15 hours ago • loading... • Updated 55 minutes ago

2.2% A1C Reduction: Lilly's Mounjaro Achieves Breakthrough in First-Ever Youth Type 2 Diabetes Trial

Phase 3 SURPASS-PEDS trial shows Mounjaro reduced A1C by 2.2% and BMI by 11.2% in children with type 2 diabetes. 86.1% achieved target A1C of ≤6.5% at 30 weeks.

27 Articles

Bennington Banner

+24 Reposted by 24 other sources

Center

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week extension

15 hours ago

Read Full Article

Israel Hayom

New Study Reveals: the Weight Loss Shot that Helps Teenagers with Type 2 Diabetes

The study included 10 to 17-year-olds with type 2 diabetes, and was presented at the European Diabetes Association conference in Vienna. • Following the results, a change in age registration is expected.

55 minutes ago

Read Full Article

stocktitan.net

2.2% A1C Reduction: Lilly's Mounjaro Achieves Breakthrough in First-Ever Youth Type 2 Diabetes Trial

Phase 3 SURPASS-PEDS trial shows Mounjaro reduced A1C by 2.2% and BMI by 11.2% in children with type 2 diabetes. 86.1% achieved target A1C of ≤6.5% at 30 weeks.

15 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year